Indiana

The Family and Social Services Administration (FSSA) posted several bulletins of interest to pharmacies. 

  • BT202306 – Pharmacy updates approved by Drug Utilization Review Board January 2023 
  • BT202304 – IHCP [Indiana Health Coverage Programs] announces end to member continuous eligibility 
  • BT2022118 – Pharmacy updates approved by Drug Utilization Review Board December 2022 

For more information, contact NACDS’ Mary Staples at 817-442-1155.

2023-02-17T11:23:23-05:00February 17, 2023|Indiana|

Iowa

The Board of Pharmacy announced the following effective March 15: 

  • ARC 6843C has been adopted and amends Chapter 10, “Controlled Substances” placing one substance into Schedule I of the Iowa Controlled Substances Act (CSA) in alignment with . 
  • ARC 6844C has been adopted and amends Chapter 37, “Iowa Prescription Monitoring Program” establishing council membership information for the PMP Advisory Council and clarifying that only overdoes-reversal opioid antagonists are required to be submitted to the PMP.  

Also in Iowa, the Board of Pharmacy issued a “Notice of Intended Action” related to ARC 6874C amending Chapter 10, “Controlled Substances,” and Chapter 12, “Precursor Substances.” This proposed rulemaking temporarily adds four substances to Schedule I, excludes one substance from Schedule II and adds one substance as a precursor substance to the Iowa CSA in alignment with response to similar action taken by the DEA ARC 6874C amending Chapter 10, “Controlled Substances,” and Chapter 12, “Precursor Substances.” This proposed rulemaking temporarily adds four substances to Schedule I, excludes one substance from Schedule II and adds one substance as a precursor substance to the Iowa CSA in alignment with DEA’s action. Comments may be submitted until 4:30 p.m. on February 28. 

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

2023-02-17T11:22:49-05:00February 17, 2023|Iowa|

Louisiana

The Department of Health (LDH) announced that they now plan to migrate Medicaid to a single payor system on October 1. All patients will be assigned to a managed care organization and will receive a new universal prescription benefit card. 

Also in Louisiana, the Board of Pharmacy met on February 15 & 16.

For more information, contact NACDS’ Mary Staples at 817-442-1155.

2023-02-17T11:22:01-05:00February 17, 2023|Louisiana|

Massachusetts

MassHealth, the state Medicaid agency, is asking pharmacies to post this flier for notice to recipients of the planned redetermination of all MassHealth beneficiaries that will begin on April 1. One half million Massachusetts residents were added to MassHealth under the PREP Act and individuals may lose their MassHealth coverage and be moved to other state sponsored or commercial health plans.

For more information, please contact NACDS’ Ben Pearlman at 617-515-2603.

2023-02-17T11:21:26-05:00February 17, 2023|Massachusetts|

Missouri

The revised 2023 Pharmacy Practice Guide is available on the Board’s website. It contains updated compliance tips and information on recent statutory/rule changes, including: 

  1. Pharmacy Working Conditions
  2. Technician Supervision & Expanded Technician Activities
  3. Electronic Final Product Verification (Pharmacists)
  4. Technology-Assisted Product Verification (Interns & Technicians), & 
  5. Quality Assurance  

Also in Missouri, the Department of Health and Senior Services recently issued a revised naloxone standing order. 

For more information, contact NACDS’ Mary Staples at 817-442-1155.

2023-02-17T11:20:53-05:00February 17, 2023|Missouri|

Montana

HB 379, extending the prohibition on PBMs to require federally certified health entities to identify 340B drug from June 1, 2023 to June 1, 2025, was amended and passed the House Business and Labor Committee on February 14.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

2023-02-17T11:19:53-05:00February 17, 2023|Montana|

Nebraska

The Department of Health and Human Services (DHHS) issued Bulletin 23-04: Nebraska Medicaid Managed Care Contracts 2024. Contracts between DHHS and Molina Healthcare of Nebraska, Nebraska Total Care and United Healthcare have been signed and these organizations will prepare to provide services under the new contract beginning January 1, 2024. 

Also in Nebraska, DHHS posted the draft minutes from the November 15, 2022, Drug Utilization Review Board meeting. 

Finally in Nebraska, LB 778, amending the Pharmacy Benefit Manager Licensure and Regulation Act, has been scheduled for a hearing on March 21. 

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

2023-02-17T11:19:18-05:00February 17, 2023|Nebraska|

New York

On February 15, the Department of Financial Services published a proposed rule regarding General Duties, Accountability and Transparency Provisions for Pharmacy Benefit Managers. The proposed rule sets forth to clarify, define and limit the duties, obligations, requirements and other provisions relating to pharmacy benefit managers under Public Health Law section 280-a(2) and provides a safe harbor provision for compliance with the regulation. It also defines, limits and clarifies the requirements for pharmacy benefit managers to provide an accounting to health plans and sets forth the terms and conditions of contract relating to pharmacy benefit management services provided to health plans by the pharmacy benefit managers, including provisions related to an appeal to the bureau for a determination on disclosure.

On February 13, NACDS participated in the Community Pharmacy Association of New York State lobby day. NACDS joined with members to advocate for Gov. Kathy Hochul’s (D) budget proposal, including the Medicaid Fee-for-Service transition effective on April 1.  

For more information, please contact NACDS’ Ben Pearlman at 617-515-2603.

2023-02-17T11:18:46-05:00February 17, 2023|New York|
Go to Top